[Monitoring hearing during ototoxic cisplatin therapy].
In the 1983-1988 period, the audition of 17 children was studied prior to and during antineoplastic chemotherapy with cumulative total cisplatin doses from 270 to 1530 mg/m2. The hearing tests were conducted by means of an objective method which doses not depend on patients' cooperation: the recording of fast auditory evoked potentials. Tone threshold audiograms were additionally obtained from cooperative children. Of the 17 patients, 14 showed a dose-dependent symmetric hearing loss which in part was severe and related in particular to the high-frequency domain. Three patients exhibited no hearing impairment even though the total cisplatin dose applied ranged from 630 to 810 mg/m2. To conclude, while allowing for reports in the literature, recommendations are given on how hearing impairment can be minimised in view of the priority of the antineoplastic action of cisplatin.
Kluba
J
J
Klinik für Hals-Nasen-Ohrenkrankheiten, Medizinischen Akademie Magdeburg.
Kluba
U
U
von Specht
H
H
Mittler
U
U
D000293:Adolescent; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D006313:Hearing Loss, Central / Q000139:chemically induced*; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced*; D006801:Humans; D007223:Infant; D009369:Neoplasms / Q000188:drug therapy*
D002945:Cisplatin
Zur Uberwachung des Gehörs während der ototoxischen Cisplatin-Therapie.